All Blogs / Industries / Medical / Pharmaceutical / New

Drug Channels News Roundup, July 2016: Biosimilars, Drug Prices, Morris & Dickson

The hot and hazy days of summer are here. Go for a swim to cool off and then enjoy this refreshing selection of articles with the Drug Channels seals of approval. In this issue: Great HBS research on biosimilars in Europe An entertaining...Show More Summary

Perspectives Toward the Elimination of Hepatitis B

Professor Guangxiang (George) Luo discusses recent advances in antiviral drug development and hepatitis B immunization which hold great promise for achieving the WHO goal of eliminating viral hepatitis by 2030. The World Health Organization (WHO)

Week 4 of the Special Issue on Preventing Diabetes

PLOS Medicine Senior Editor Richard Turner discusses the fourth and final week of the Special Issue on Preventing Diabetes. Read about week one Read about week two Read about week three This fourth and ultimate week of PLOS Medicine...

How Specialty Pharmacy Is Penetrating Buy-and-Bill Oncology Channels

The distribution channel for provider-administered oncology drugs is undergoing significant change—notwithstanding the Centers for Medicare & Medicaid Services’ (CMS) misguided and controversial Part B Drug Payment Model. As you will...Show More Summary

FDA's Dependence on User Fees & "Institutional Corruption" Blamed for Dramatic Increase in Drug Adverse Events and Deaths

Did you know that prescription drugs are the 4th leading cause of death in the U.S.? This does not include deaths and hospitalizations from over-dosing, errors, or recreational drug use. We know this because of  hundreds of thousands...Show More Summary

Hub and SPP Model Optimization

7th Hub and SPP Model OptimizationSeptember 29-30, 2016 | San Diego, mounting cost pressures and increased demands for affordable, value-based treatment options, bio/pharma teams face an increasingly competitive market. Show More Summary

Novartis Respects the Patient Perspective and Pays for It Too! But Is It Absolutely Transparent?

On, David Palacios, Head of Global Patient Relations, and Sanja Njegic, Head of Patient Advocacy & Relations in Europe at Novartis, explain how their company has moved from working with doctors and payers to working directly with patients. Show More Summary

Weekly Roundup 7.22.16

Well, it is really hot. Really really hot. And I am moving kind of slow, as one should probably do in the summer. I didn’t even get to the Weekly Roundup last week, which means that some of what I … Continue reading ?

Fifty Ways to Leave the GOP

This morning I saw this tweet by a journalist: Talk about "Open Carry" in Ohio - This is "Open Nazism!" Any way, here's my response that I couldn't convert via Twitter: Read more »

Latest CMS Forecast Shows Big Drug Spending Growth Through 2025

Last week, the Centers for Medicare & Medicaid Services (CMS) released its latest forecasts for national health expenditures. See the Health Affairs article: National Health Expenditure Projections, 2015–25: Economy, Prices, And Aging Expected To Shape Spending And Enrollment. Show More Summary

Dementia across the lifespan and around the globe—Pathophysiology, prevention, treatment, and societal impact: a Call for Papers

The PLOS Medicine Editors announce a Special Issue on Dementia to be guest edited by Dr. Carol Brayne and Dr. Bruce Miller. Submissions are now being accepted ahead of the deadline of September 30. PLOS

Real Dog Patient Stories Send Sales of Sileo Rocketing!

"Data gives credibility, but stories provide truth," says Ash Rishi, Co-Founder and Managing Director of COUCH (read "Patient Storytelling Marketing"). Social media and patient stories are a "match made in heaven" and several pharmaShow More Summary

Apple's ResearchKit Mobile Apps Make Strides in Clinical Research, But Is iPhone User Demographics an Issue?

As reported in the trade media, GSK developed an iPhone app for use in "clinical research" (read "GSK Develops Rheumatoid Arthritis App for Clinical Trial Using Apple's ResearchKit"). It is claimed that this "[marks] the first time a...Show More Summary

Week 3 of the Special Issue on Preventing Diabetes

 PLOS Medicine Senior Research Editor Clare Garvey on week three of the Special Issue on Preventing Diabetes Read about week one Read about week two Week three of the PLOS Medicine Special Issue on Preventing Diabetes brings

Reality Check: 340B is 4% (not 2%) of the U.S. Drug Market—And Growing Quickly

Many 340B lobbyists frequently claim that the 340B Drug Pricing Program amounts to “only 2%” of total U.S. drug purchases and is therefore not a significant issue. This is an extremely careless misrepresentation of the truth. As I document below, 340B now accounts for at least 4% of the U.S. Show More Summary

Coupon and Co-Pay Offer Design Optimization

CBI’s 4th Annual Coupon and Co-Pay Offer Design Optimization September 15-16, 2016 | Philadelphia, PA Exclusive Offer – Register by 8/12/2016 and save $500 (mention promo code COUPAF) Think coupon and co-pay programs are going away?Show More Summary

Copyright © 2015 Regator, LLC